Is mitochondrial donation germ-line gene therapy? Classifications and ethical implications

Bioethics

Volumn 31, Issue 1, 2017, Pages 55-67

  Newson, Ainsley J ^a   Wrigley, Anthony ^b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b KEELE UNIVERSITY   (United Kingdom)

Author keywords

Ethics; Gene therapy; Genetic modification; Germ line; Identity; Mitochondrial disease; Mitochondrial donation; Mitochondrial replacement

Indexed keywords

BIOETHICS; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ETHICS; GENE THERAPY; GENETIC ENGINEERING; GENETICS; GERM CELL; HUMAN; MITOCHONDRIAL REPLACEMENT THERAPY; MITOCHONDRION; SOCIAL PSYCHOLOGY;

BIOETHICS; GENETIC ENGINEERING; GENETIC THERAPY; GERM CELLS; HUMANS; MITOCHONDRIA; MITOCHONDRIAL DISEASES; MITOCHONDRIAL REPLACEMENT THERAPY; SOCIAL VALUES;

EID: 85010850268     PISSN: 02699702     EISSN: 14678519     Source Type: Journal    
DOI: 10.1111/bioe.12312     Document Type: Article

References (91)

1. Protein Cell 2015; 6: 363-372
2. X Kang, et al. Introducing precise geneticmodifications into human 3PN embryos by CRISPR/Cas-mediated genome editing. J Assist Reprod Genet 2016; 33: 581-588.
3. Gene therapy in man. Recommendations of European Medical Research Councils. Lancet 1988; 1: 1271-1272
4. UNESCO. 1997. Universal Declaration on the HumanGenome andHuman Rights. Available at: http://portal. unesco.org/en/ev.php-URL_ID513177&URL_DO5DO_TOPIC&URL_ SECTION5201.html [Accessed 4 Jan 2016]: Art 24
5. Council of Europe. 1997. Convention for the Protection of Human Rights and Dignity of the Human Being with regard to theApplication of Biology andMedicine: Convention on Human Rights and Biomedicine. Oviedo, Spain: Council of Europe:Art. 13. For a summaryof relevantnational laws
6. T. Ishii. Potential impact of human mitochondrial replacement on global policy regarding germline gene modification.Reprod Biomed Online 2014; 29: 150-155.
7. M.D. Bacchetta & G. Richter. Response to “Germ-line therapy to cure mitochondrial disease: protocol and ethics of in vitro ovum nuclear transplantation” by Donald S. Rubenstein, David C. Thomasma, Eric A. Schon, and Michael J. Zinaman (CQ Vol 4, No 3). Camb Q Healthc Ethics 1996; 5: 450-457
8. J.J. Pasternack. 2005.An Introduction to HumanMolecularGenetics: Mechanisms of Inherited Diseases, 2nd ed. Hoboken, NJ: John Wiley & Sons, Chapter 12
9. P.D. Turnpenny. 2012. Emery’s Elements of Medical Genetics. 14Thed. St Louis, US:Churchill Livingstone: 181-183, Chapters 2, 7& 11.
10. S. Adhya, et al. Mitochondrial gene therapy: The tortuous path from bench to bedside. Mitochondrion 2011; 11: 839-844.
11. H. Cwerman-Thibault et al. Mitochondrial medicine: to a new era of gene therapy for mitochondrial DNA mutations. J Inherit Metab Dis 2011; 34: 327-344
12. Y.S. Ng & D.M. Turnbull. Mitochondrial disease: genetics and management. J Neurol 2016; 263: 179-91.
13. T. Lewens. 2015. The Biological Foundation of Bioethics. Oxford: Oxford University Press: Chapter 1.
14. H. Adams. A human germline modification scale. J Law Med Ethics 2004; 32: 164-173.
15. E. Juengst & E. Parens. 2003. Germ-line dancing: definitional considerations for policy makers. In Designing our Descendants: The Promises and Perils of Genetic Modifications. A.R. Chapman & M.S. Frankel, eds. Baltimore: The Johns Hopkins University Press: 20-36
16. A.L. Bonnicksen. Transplanting nuclei between human eggs: Implications for germ-line genetics. Polit Life Sci 1998; 17: 3-10.
17. Human Fertilization and Embryology Authority. Undated. New techniques to prevent mitochondrial disease. London: HFEA. Available at: http://mitochondria.hfea.gov.uk/mitochondria/what-is-mitochondrial-disease/newtechniques-to-prevent-mitochondrial-disease/[Accessed 4 Jan 2016].
18. T. Morrow. 2015. Is gene editing mtDNA an alternative to mitochondrial replacement therapy? Sussex, UK: Ted’s Blog. Available at: https://tedmorrow.wordpress.com/2015/04/24/is-gene-editing-mtdna-an-alternative-to-mitochondrial-replacement-therapy/[Accessed 19 August 2015]
19. T. Ishii. Germline genome-editing research and its socioethical implications. Trends Mol Med 2015; 21: 473-481
20. P. Reddy et al. Selective elimination of mitochondrial mutations in the germline by genome editing. Cell 2015; 161: 459-469.
21. R.F. Chadwick. 2009. Gene therapy. In A Companion to Bioethics, 2nd ed. H.Kuhse& P. Singer, eds.Oxford: Blackwell Publishing: 207-215.
22. Genetics Home Reference. 2015. What is gene therapy? Washington, DC: US National Institutes of Health. Available at: http://ghr.nlm.nih.gov/handbook/therapy/genetherapy [Accessed 5 Jan 2016].
23. Better Health Channel. 2011. Gene therapy. Melbourne: Victoria State Government. Available at: https://www.betterhealth.vic.gov.au/health/conditionsandtreatments/gene-therapy [Accessed 5 Jan 2016].
24. Your Genome. 2015. What is gene therapy? Cambridge: Wellcome Genome Campus. Available at: http://www.yourgenome.org/facts/whatis-gene-therapy [Accessed 5 Jan 2016].
25. D.R. Thorburn et al. The pros and cons of mitochondrial manipulation in the human germline. Mitochondrion 2001; 1: 123-127.
26. Public Health Directorate/Health Science and Bioethics Division. 2014.MitochondrialDonation:Aconsultation on draft regulations to permit the use of new treatment techniques to prevent the transmission of a seriousmitochondrial disease from mother to child. London: Department of Health. Available at: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/285251/mitochondrial_donation_consultation_ document_24_02_14_Accessible_V0.4.pdf [Accessed 26 Aug 2015]: 13. The implication here being that if a change is not significant, it does not constitute gene therapy (of any kind).
27. C.T. Moraes et al. Manipulating mitochondrial genomes in the clinic: playing by different rules. Trends Cell Biol 2014; 24: 209-211: 211.
28. Nuffield Council on Bioethics. 2012. Novel techniques for the prevention of mitochondrial DNA disorders: an ethical review. London: Nuffield Council on Bioethics. Available at: http://nuffieldbioethics.org/project/mitochondrial-dna-disorders/[Accessed 4 Jan 2016].
29. H. Li, et al. Physiology and pathophysiology of mitochondrial DNA. Adv Exp Med Biol 2012; 942: 39-51
30. G. Hudson et al. Two-stage association study and meta-analysis of mitochondrial DNA variants in Parkinson’s disease. Neurology 2013; 80: 2042-2048
31. H. Bulstrode et al. Mitochondrial DNA and traumatic brain injury. Ann Neurol 2014; 75: 186-195
32. M.C. Kennedy et al. Mitochondrial DNAvariants mediate energy production and expression levels for CFH, C3 and EFEMP1 genes: implications for age-related macular degeneration. PLoS One, 2013; 8: e54339
33. A.L. Bredenoord, et al. Ooplasmic and nuclear transfer to prevent mitochondrial DNA disorders: conceptual and normative issues. Hum Reprod Update 2008; 14: 669-678.
34. M. Tachibana, et al. Towards germline gene therapy of inherited mitochondrial diseases. Nature 2013; 493: 627-631
35. S. Di Mauro, et al. Approaches to the treatment of mitochondrial diseases. Muscle Nerve 2006; 34: 265-283.
36. D.B. Resnik & P.J. Langer. Human germline gene therapy reconsidered. Hum Gene Ther 2001; 12: 1449-1458.
37. A. Weismann. 1891. Essays upon Heredity and Kindred Biological Problems. Oxford: Oxford University Press
38. I. Kerridge, et al. 2013. Ethics and Law for the Health Professions, 4Thed. Sydney: The Federation Press: 1089.
39. M.S. Frankel & B.T. Hagen. 2011. Germline therapies. London: Nuffield Council on Bioethics. Available at: http://nuffieldbioethics.org/wpcontent/uploads/Germline_therapies_background_paper.pdf [Accessed 15 June 2015]: 1.
40. M.S. Frankel & A.R. Chapman. 2000. Human Inheritable Genetic Modifications: Assessing Scientific, Ethical, Religious and Policy Issues. United States: American Association for the Advancement of Science. Available at: http://www.aaas.org/sites/default/files/migrate/uploads/germline.pdf [Accessed 18 Aug 2015]: 61.
41. W.F. Anderson. Human gene therapy: why draw a line? J Med Philos 1989; 14: 681-693: 682
42. L. Walters & J.G. Palmer. 1997. The Ethics of Human Gene Therapy. NewYork: Oxford University Press: 62.
43. J.C. Fletcher & W.F. Anderson. Germ-line gene therapy: a new stage of debate. Law Med Health Care 1992; 20: 26-39.
44. E.M. Berger & B.M. Gert. Genetic disorders and the ethical status of germ-line gene therapy. J Med Philos 1991; 16: 667-683.
45. M. Lapp_e. Ethical issues in manipulating the human germ line. J Med Philos 1991; 16: 621-639.
46. J.E.J. Rasko et al. 2006. Is inheritable genetic modification the new dividing line? In The Ethics of Inheritable Genetic Modification: A Dividing Line? J.E.J. Rasko et al., eds. Cambridge: Cambridge University Press: 1-15
47. NESCI. 2008. Briefing paper on the need to protect the future possibility of treating mitochondrial disease and other conditions by a procedure that involves mitochondrial transplantation. Newcastle: NorTheast England Stem Cell Institute. Available at: http://www.ncl.ac.uk/nesci/assets/docs/NESCIbriefon2008HFEbill-MitochondrialTransplants-Vers01-6.pdf [Accessed 3 Jul 2015]
48. Public Health Directorate/Health Science and Bioethics Division. 2014. Mitochondrial Donation: Government response to the consultation on draft regulations to permit the use of new treatment techniques to prevent the transmission of a serious mitochondrial disease from mother to child. London: Department of Health. Available at: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/332881/Consultation_response.pdf [Accessed 25 Aug 2015]:
49. E.H. Morrow et al. Risks inherent to mitochondrial replacement. EMBO Rep 2015; 16: 541-544
50. K Reinhardt et al. Mitochondrial replacement, evolution, and the clinic. Science 2013; 341: 1345-1346
51. D.B. Sloan et al. Mitonuclear linkage disequilibrium in human populations. Proc. R. Soc. B, 282: 20151704
52. N. Gemmell and J.N. Wolff. Mitochondrial replacement therapy: Cautiously replace the master manipulator. BioEssays 2015 37: 584-585
53. K.J Dunham-Snary and S.W Ballinger. Mitochondrial-nuclear DNA mismatch matters. Science 2015; 349: 1449-1450.
54. National Academies of Sciences, Engineering, and Medicine. 2016. Mitochondrial Replacement Techniques: Ethical, Social, and Policy Considerations. Washington, DC: The National Academies Press. Chapter 3, p.7ff. Available at http://www.nap.edu/21871 [Accessed 4 Feb 2016],We discuss this approach further below.
55. J. Poulton et al. Transmission of mitochondrial DNA diseases and ways to prevent them. PLoS Genet 2010; 6
56. H.S. Lee et al. Rapid mitochondrial DNA segregation in primate preimplantation embryos precedes somatic and germline bottleneck. Cell Rep 2012; 1: 506-515
57. I.J. Wilson et al. Mitochondrial DNA sequence characteristics modulate the size of the genetic bottleneck. Hum Mol Gen 2016; 25: 1031-41.
58. H.J.M. Smeets. Preventing the transmission of mitochondrial DNA disorders: selecting the good guys or kicking out the bad guys. Reprod Biomed Online 2013; 27: 599-610.
59. A.L Bredenoord, et al. Avoiding transgenerational risks of mitochondrial DNA disorders: a morally acceptable reason for sex selection? Hum Reprod 2010; 25: 1354-1360
60. J.B. Appleby. The ethical challenges of the clinical introduction of mitochondrial replacement techniques. Med Health Care Philos 2015; 18: 501-514.
61. H. O Geen et al. How specific is CRISPR/Cas9 really? Curr Opin Chem Biol 2015; 29: 72-78.
62. G. Hamilton. The mitochondria mystery. Nature 2015; 525: 444-446
63. A.L. Bredenoord & P. Braude. Ethics of mitochondrial gene replacement: from bench to bedside. BMJ 2010; 341: c6021
64. P.F. Chinnery, et al. The challenges ofmitochondrial replacement. PLoS Genet 2014; 10: e1004315
65. H. Ma, et al. Metabolic rescue in pluripotent cells from patients with mtDNA disease. Nature 2015; 524: 234-238
66. L.A. Hyslop, et al. Towards clinical application of pronuclear transfer to prevent mitochondrial DNA disease. Nature 2016; 534: 383-6
67. M. Yamada, et al. Genetic drift can compromise mitochondrial replacement by nuclear transfer in human oocytes Cell StemCell 2016; 18: 1-6.
68. F. Baylis. The ethics of creating children with three genetic parents. Reprod Biomed Online 2013; 26: 531-534
69. M. Darnovsky. Aslippery slope to human germlinemodification. Nature 2013; 499: 127
70. D.S. Kyriakouli et al. Progress and prospects: gene therapy for mitochondrialDNA disease. Gene Ther 2008; 15: 1017-1023
71. E.Y. Adashi and I.G. Cohen. Going germline: mitochondrial replacement as a guide to genome editing. Cell 2016; 164: 832-835.
72. J.A. Robertson. Oocyte cytoplasm transfers and the ethics of germline intervention. J Law Med Ethics. 1998; 26: 179, 211-220.
73. F. Baylis & J.S. Robert. 2006. Radical rupture: exploring biological sequelae of volitional inheritable genetic modification. In The Ethics of Inheritable Genetic Modification: A Dividing Line? J.E.J. Rasko et al., eds. Cambridge: Cambridge University Press: 131-148
74. The President’s Council on Bioethics. 2003. Beyond Therapy: Biotechnology and the Pursuit of Happiness. United States: Executive Office of the President. Available at: https://repository.library.georgetown.edu/handle/10822/559341 [Accessed 6 Jan 2016].
75. A. Buchanan. 2011. Beyond Humanity? The Ethics of Biomedical Enhancement. Oxford and New York: Oxford University Press
76. J. Savulescu et al. eds. 2011. Enhancing Human Capacities. New York: Wiley-Blackwell
77. F.M. Kamm. Is there a problem wiThenhancement? Am J Bioeth 2005; 5: 5-14
78. P.H. Schwartz. Defending the distinction between treatment and enhancement. Am J Bioeth 2005; 5: 17-19.
79. M.J. Mehlman. HowWillWe Regulate Genetic Enhancement? Wake Forest L Rev 1999; 34: 671-617
80. S. Wilkinson. 2010. Choosing Tomorrow’s Children. Oxford: Oxford University Press
81. A.Wrigley, et al. Mitochondrial Replacement: Ethics and Identity. Bioethics 2015; 29: 631-638.
82. D. Parfit. 1984. Reasons and Persons. Oxford: Oxford University Press
83. J. Feinberg. Wrongful life and the counterfactual element in harming. Soc Philos Policy 1987; 4: 145-178
84. M. Hanser. Harming future people. Philos Public Aff 1990; 19: 47-70
85. D. Velleman. Persons in prospect. Philos Public Aff 2008; 36: 221-288
86. A. Wrigley. Genetic selection and modal harms. Monist 2006; 89: 505-525
87. A. Wrigley. Harm to future persons: non-identity problems and counterpart solutions. Ethical Theory Moral Pract 2012; 15 175-190
88. D. Lewis. 1986. On the Plurality of Worlds. Oxford: Blackwell
89. P. Mackie. 2006. How Things Might Have Been: Individuals, Kinds, and Essential Properties. Oxford: Oxford University Press.
90. S.M. Liao. The organism view defended. Monist 2006; 89: 334-350.
91. K.R. Smith. Gene Therapy: Theoretical And Bioethical Concepts. Arch Med Res 2003; 34: 247-268